中國宏光(8646.HK)首日上市高開23.38%
格隆匯1月13日丨產銷建築玻璃產品商中國宏光(8646.HK)今日首日上市高開23.38%,開報0.95港元,盤前成交750.83萬港元,最新總市值2.85億港元。該股IPO價格0.77港元,招股區間的下限定價,超購倍數約27.90倍。
公司所得款項淨額總額估計約為1920萬港元。其中,約51.3%用於升級集團現有生產設施;約10.8%用於償還銀行貸款;約12.9%用於提升集團的研發能力;約14.4%用於加強信息技術、生產安全及環保基建設施;約5.6%用於擴大集團銷售及市場範圍;約5.0%用於為集團的營運資金及其他一般企業用途提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.